Medication Related Osteonecrosis of the Jaw Treatment Guidelines

Understanding Medication-Related Osteonecrosis of the Jaw (MRONJ)

Medication-related osteonecrosis of the jaw (MRONJ) is a severe, potentially debilitating condition characterised by the progressive death and exposure of bone within the maxillofacial skeleton. It occurs in patients who are receiving, or have previously received, specific antiresorptive or antiangiogenic pharmacological agents, without any history of radiation therapy to the head and neck region. The alveolar bone of the jaw—comprising the mandible (lower jaw) and maxilla (upper jaw)—is uniquely susceptible due to its rapid bone turnover rate, constant exposure to oral microflora, and the thin overlying mucosal barrier subject to physiological masticatory trauma.

The fundamental biological definition established by international surgical bodies requires the presence of exposed bone, or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region, that persists for more than eight weeks in an individual with relevant medication exposure. The mandible is affected substantially more often than the maxilla, with a ratio of roughly two to one, primarily due to its comparatively limited, single-artery blood supply compared to the rich, collateral vascular network supporting the upper jaw.

Pharmacological Causes and Underlying Risk Factors

MRONJ is primarily precipitated by two major classes of medications: antiresorptive agents (such as bisphosphonates like zoledronic acid, pamidronate, alendronate, and the RANKL-inhibitor denosumab) and antiangiogenic therapies (including tyrosine kinase inhibitors like sunitinib and monoclonal antibodies targeting VEGF like bevacizumab). Antiresorptive drugs fundamentally inhibit osteoclasts—the cells responsible for bone resorption—which severely halts physiological remodelling and compromises the bone's intrinsic ability to repair micro-damage. Antiangiogenic drugs impair the formation of new blood vessels, depriving the underlying osseous tissue of oxygen, nutrients, and immune cells.

The risk profile varies dramatically based on drug indication, dosage, and duration. Oncology patients receiving high-dose intravenous bisphosphonates or monthly denosumab for bone metastases or multiple myeloma carry a substantially higher risk compared to osteoporosis patients taking lower-dose oral formulations. Local triggers amplify this risk, with invasive dental procedures such as tooth extractions, dental implant placement, and periodontal surgery representing the primary precipitating events. Concomitant systemic factors include poorly controlled diabetes mellitus, chronic corticosteroid therapy, smoking, and advanced age.

Regional cultural factors also modulate local tissue susceptibility. In Indian and South Asian populations, widespread use of chewable tobacco, gutka, and betel nut (paan) induces chronic chemical trauma, accelerates mucosal atrophy, and exacerbates aggressive periodontal disease. These lifestyle factors, coupled with systemic barriers to routine preventive dental screening prior to initiating oncology regimens, significantly compound the risk of tissue breakdown and secondary osteomyelitis in the jaw.

Recognising MRONJ Jaw Symptoms and Clinical Presentation

The clinical presentation of MRONJ jaw symptoms ranges from subtle, subclinical changes to extensive, debilitating bone necrosis. In the earliest stages, patients may experience prodromal symptoms such as unexplained, dull, aching bone pain, altered neurosensory perception (such as Vincent's sign, characterised by numbness, tingling, or parasthesia of the lower lip and chin), and sudden loosening of teeth without prior periodontal breakdown. As the necrosis advances, the hallmark clinical sign emerges: areas of exposed, rough, yellow-grey, dead cortical bone that fail to heal.

Surrounding soft tissues frequently exhibit chronic inflammation, erythema, swelling, and mucosal ulceration. Secondary bacterial infection of the exposed necrotic bone generates persistent purulent discharge (pus), severe oral malodour (halitosis), and regional lymphadenopathy (swollen lymph nodes under the jaw and neck). In advanced presentations, deep infection pathways form chronic sinus tracts or extraoral fistulas, where pus discharges directly through the facial skin, accompanied by soft tissue breakdown, trismus (difficulty opening the mouth), and significant impairment in chewing and speech.

Diagnostic Pathway, Imaging, and Differential Diagnosis

Accurate diagnosis of MRONJ relies upon a thorough medical history, comprehensive clinical examination, and high-resolution diagnostic imaging. Clinicians conduct careful intraoral probing to detect occult bone exposure beneath fistulous openings and examine neurosensory function along the inferior alveolar nerve pathway. Orthopantomograms (panoramic dental X-rays) offer a baseline overview, but Cone Beam Computed Tomography (CBCT) or multi-slice CT scanning is the standard of care for mapping the true three-dimensional extent of disease. Imaging typically reveals osteosclerosis, thickened lamina dura, osteolysis, persistent unhealed extraction sockets, and cortical sequestration.

Magnetic resonance imaging (MRI) is often utilised in complex oncology cases to evaluate bone marrow oedema and soft tissue involvement, while radionuclide bone scintigraphy can identify early hypermetabolic alterations before cortical changes appear on plain radiographs. Differential diagnosis is critical and involves distinguishing MRONJ from osteoradionecrosis (which requires a history of radiotherapy), chronic suppurative osteomyelitis, alveolar osteitis (dry socket), primary jaw malignancies, and metastatic disease to the jaw, particularly in cancer patients with known primary tumours.

Clinical Staging Systems: The AAOMS Framework

The staging framework established by the American Association of Oral and Maxillofacial Surgeons (AAOMS) standardises clinical assessment and guides therapeutic intervention. The system begins with the 'At-Risk' category, comprising patients who have been exposed to antiresorptive or antiangiogenic medications but exhibit no apparent necrotic bone or clinical symptoms. Stage 0 (non-exposed disease) describes patients presenting with non-specific clinical symptoms, such as jaw pain, tooth mobility, or radiographic changes, in the absence of clinically visible exposed bone.

Stage 1 is defined by exposed, necrotic bone or fistulae that probe to bone in patients who are completely asymptomatic and show no evidence of active regional infection or soft tissue inflammation. Stage 2 involves exposed bone or fistulae associated with pain, clinical signs of infection (erythema, purulence), and localised soft tissue swelling. Stage 3 represents the most severe presentation, featuring exposed necrotic bone extending beyond the alveolar ridge (into the inferior border of the mandible, maxillary sinus, or zygoma), accompanied by complications such as pathological fractures, extraoral cutaneous fistulae, or extensive soft tissue breakdown.

Evidence-Based Treatment Protocols: Conservative vs Surgical Management

The overarching goal of MRONJ treatment is to control pain, manage secondary infection, arrest the progression of bone necrosis, and preserve oral health-related quality of life. Traditionally, management heavily favoured conservative therapy, particularly for early stages. Conservative protocols combine chlorhexidine digluconate (0.12% to 0.2%) antimicrobial mouth rinses, meticulous professional hygiene, superficial smoothing of sharp bone margins to protect soft tissues, and targeted systemic antibiotic regimens (such as amoxicillin-clavulanate, clindamycin, or doxycycline) during acute infectious exacerbations.

While conservative measures effectively manage symptoms in many patients, contemporary surgical literature supports early, definitive surgical intervention in appropriate candidates to achieve mucosal coverage and long-term resolution. Surgical strategies range from conservative debridement (removal of loose, necrotic sequestra) and peripheral ostectomy (resecting non-viable bone back to bleeding, vascularised osseous margins) to extensive segmental mandibulectomy or maxillectomy for Stage 3 disease. Adjunctive therapies such as platelet-rich fibrin (PRF), low-level laser therapy (photobiomodulation), and fluorescence-guided surgery using tetracycline marking are increasingly integrated into surgical protocols to enhance mucosal healing.

What to Expect: The Step-by-Step Clinical Experience

When attending a specialised oral and maxillofacial clinic for MRONJ management, the patient undergoes a structured, multidisciplinary evaluation. The appointment begins with a detailed pharmacological audit, reviewing drug types, cumulative dosage, administration route, and oncological or rheumatological history. A gentle clinical examination follows, during which the clinician maps mucosal defects, palpates for tenderness, assesses tooth mobility, and records periodontal indices. Cross-sectional CBCT imaging is usually captured during this baseline assessment to evaluate the sub-mucosal bone architecture.

If a non-surgical approach is planned, the clinician performs gentle irrigation of the exposed area with sterile saline or antiseptic solution, relieves sharp bony crests using round diamond burs under copious irrigation, and provides oral hygiene instruction alongside targeted prescriptions. If surgical debridement or bone resection is indicated, the procedure is carried out under local anaesthesia with intravenous sedation or general anaesthesia. The surgeon raises a full-thickness mucoperiosteal flap, removes non-viable bone using piezosurgery or rotary instruments until healthy, bleeding bone is reached, smoothens all sharp edges, and achieves tension-free primary soft tissue closure over the site.

Post-Treatment Recovery, Healing Timelines, and Aftercare

Recovery following surgical or conservative MRONJ intervention requires close monitoring and adherence to aftercare protocols. In the immediate post-operative phase (the first 7 to 14 days), mild to moderate swelling, localized discomfort, and minor blood-tinged saliva are expected. Patients are prescribed suitable analgesics, a course of culture-guided or broad-spectrum systemic antibiotics, and non-staining antiseptic rinses. The diet must strictly consist of soft, high-protein foods, avoiding hard, crunchy, hot, or spicy items that could traumatise the fragile healing mucosa.

Complete mucosal epithelialisation often requires 4 to 8 weeks due to the underlying suppression of bone remodelling and microvascular compromise. Patients must refrain from using removable dental prostheses (dentures) over the treated surgical site during this initial period, as mechanical pressure can disrupt the surgical flap and trigger recurrent bone exposure. Follow-up appointments are scheduled at weekly or fortnightly intervals to evaluate tissue closure, remove non-resorbable sutures if placed, and ensure no secondary fistulae develop.

Potential Complications and Complex Management Strategies

Uncontrolled or advanced MRONJ can lead to severe structural and functional complications within the craniofacial skeleton. The continuous resorption and structural weakening of the mandible can culminate in a pathological fracture, which presents with sudden acute pain, severe malocclusion, and mandibular instability. Management of pathological fractures secondary to MRONJ is exceptionally complex, often requiring segmental bone resection followed by rigid reconstruction using heavy titanium reconstruction plates and vascularised free tissue transfer (such as a microvascular fibula flap).

In the maxilla, advanced necrosis frequently breaches the cortical boundaries of the maxillary sinus and nasal cavity, leading to chronic, refractory oroantral or oronasal fistulas, sinusitis, and persistent nasal regurgitation of fluids. Soft tissue retraction may result in persistent extraoral discharging wounds on the face and neck. Managing these severe sequelae necessitates an integrated multidisciplinary team, including oral and maxillofacial surgeons, reconstructive plastic surgeons, medical oncologists, infectious disease specialists, and specialised dental clinicians.

Prevention Strategies, Pre-Therapy Clearance, and Maintenance

Prevention represents the single most effective strategy in mitigating the burden of MRONJ. Before initiating high-dose antiresorptive or antiangiogenic therapy, every patient should undergo a comprehensive, mandatory dental assessment and radiographic clearance. All unsavable teeth, active periodontal disease, chronic periapical infections, and poorly fitting prostheses must be fully treated and healed prior to commencing the pharmacological regimen. A minimum healing window of 14 to 21 days following tooth extractions is strongly advised before starting systemic bone-modifying drugs.

For patients already maintained on long-term therapy, non-surgical endodontic treatment (root canal therapy) is universally preferred over tooth extraction whenever possible. If an extraction is unavoidable, it must be performed using minimally traumatic surgical techniques, with primary soft tissue closure and perioperative antibiotic prophylaxis. Patients must maintain meticulous oral hygiene, undergo professional dental hygiene cleanings every 3 to 4 months, and completely eliminate tobacco, gutka, and alcohol consumption to protect the integrity of the oral mucosa.

Evidence and further reading

The contemporary management of MRONJ is guided by position papers and clinical practice guidelines published by leading scientific and surgical authorities. These include the American Association of Oral and Maxillofacial Surgeons (AAOMS), the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO), the British Association of Oral and Maxillofacial Surgeons (BAOMS), and guidance from the National Institute for Health and Care Excellence (NICE).

Systematic reviews published in the Journal of Oral and Maxillofacial Surgery, International Journal of Oral and Maxillofacial Surgery, and Cochrane Reviews emphasise the critical role of preventive pre-therapeutic screening, early surgical intervention for refractory lesions, and multi-professional coordination between oncologists, endocrinologists, and dental surgeons to achieve optimal clinical outcomes.